Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

PURPOSE: The market price of adebrelimab, the first Chinese-developed anti-PD-L1 antibody used as a first-line treatment for extensive stage-small-cell lung cancer (ES-SCLC), has garnered significant public attention. This study sought to investigate the affordable price of adebrelimab for Chinese p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Dongchu, Dong, Xinrui, Zhou, Zhen, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680037/
https://www.ncbi.nlm.nih.gov/pubmed/38024490
http://dx.doi.org/10.2147/RMHP.S439119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680037/
https://www.ncbi.nlm.nih.gov/pubmed/38024490
http://dx.doi.org/10.2147/RMHP.S439119

Ejemplares similares